Vir Biotechnology reported a clinical advance in hepatitis delta, with ECLIPSE 1 meeting all endpoints and SOLSTICE showing deep, sustained viral suppression. T

Vir Biotechnology reported a clinical advance in hepatitis delta, with ECLIPSE 1 meeting all endpoints and SOLSTICE showing deep, sustained viral suppression. The results bolster its late-stage treatment push as the company broadens its pipeline.